ES2418032R1 - Derivados de 2-(1-fenil-4,5,6,7-tetrahidro-1h-indazol-4-il)etilamina utiles como inhibidores de receptores sigma - Google Patents

Derivados de 2-(1-fenil-4,5,6,7-tetrahidro-1h-indazol-4-il)etilamina utiles como inhibidores de receptores sigma

Info

Publication number
ES2418032R1
ES2418032R1 ES201390057A ES201390057A ES2418032R1 ES 2418032 R1 ES2418032 R1 ES 2418032R1 ES 201390057 A ES201390057 A ES 201390057A ES 201390057 A ES201390057 A ES 201390057A ES 2418032 R1 ES2418032 R1 ES 2418032R1
Authority
ES
Spain
Prior art keywords
indazol
phenyl
derivatives
ethylamine
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201390057A
Other languages
English (en)
Other versions
ES2418032B1 (es
ES2418032A2 (es
Inventor
Arjona Jordi Corbera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of ES2418032A2 publication Critical patent/ES2418032A2/es
Publication of ES2418032R1 publication Critical patent/ES2418032R1/es
Application granted granted Critical
Publication of ES2418032B1 publication Critical patent/ES2418032B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Derivados de 2-(1-fenil-4,5,6,7-tetrahidro-1H-indazol-4-IL)etilamina útiles como inhibidores de receptores sigma. La invención se refiere a compuestos que tienen actividad farmacológica frente al receptor sigma, y más particularmente a derivados de indazol de fórmula I ****IMAGEN**** y a procedimientos de preparación de tales compuestos, a composiciones farmacéuticas que los comprenden, y a su uso en terapia y/o profilaxis, en particular para el tratamiento de psicosis o dolor.
ES201390057A 2010-12-03 2011-12-02 Derivados de 2-(1-fenil-4,5,6,7-tetrahidro-1h-indazol-4-il)etilamina útiles como inhibidores de receptores sigma Withdrawn - After Issue ES2418032B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382327A EP2468728A1 (en) 2010-12-03 2010-12-03 2-(1-phenyl-4,5,6,7-tetrahydro-1H-indazol-4-YL)ethylamine derivatives useful as sigma receptor inhibitors
EP10382327 2010-12-03
PCT/EP2011/071613 WO2012072791A2 (en) 2010-12-03 2011-12-02 2-(1-phenyl-4,5,6,7-tetrahydro-1h-indazol-4-yl)ethylamine derivatives useful as sigma receptor inhibitors

Publications (3)

Publication Number Publication Date
ES2418032A2 ES2418032A2 (es) 2013-08-09
ES2418032R1 true ES2418032R1 (es) 2013-11-07
ES2418032B1 ES2418032B1 (es) 2014-10-06

Family

ID=43501083

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201390057A Withdrawn - After Issue ES2418032B1 (es) 2010-12-03 2011-12-02 Derivados de 2-(1-fenil-4,5,6,7-tetrahidro-1h-indazol-4-il)etilamina útiles como inhibidores de receptores sigma

Country Status (3)

Country Link
EP (1) EP2468728A1 (es)
ES (1) ES2418032B1 (es)
WO (1) WO2012072791A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2016000254A1 (en) * 2013-12-20 2017-10-06 Esteve Labor Dr Fused imidazolyl derivatives, their preparation and use as medicaments.
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021463A1 (en) * 2004-08-27 2006-03-02 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP2196458A1 (en) * 2008-12-10 2010-06-16 Laboratorios Del. Dr. Esteve, S.A. Process for obtaining enantiomerically enriched pyrazole derivatives
WO2011018488A1 (en) * 2009-08-14 2011-02-17 Laboratorios Del Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021463A1 (en) * 2004-08-27 2006-03-02 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP2196458A1 (en) * 2008-12-10 2010-06-16 Laboratorios Del. Dr. Esteve, S.A. Process for obtaining enantiomerically enriched pyrazole derivatives
WO2011018488A1 (en) * 2009-08-14 2011-02-17 Laboratorios Del Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CORBERA, J. et al. ¿A Medicinal-Chemistry-Guided Approach to Selective and Druglike Sigma 1 Ligands¿ ChemMedChem 2006, Volumen 1, páginas 140-154. Ver página 140, resumen, página 142, esquema 1; página 143, tabla 1. *

Also Published As

Publication number Publication date
EP2468728A1 (en) 2012-06-27
WO2012072791A2 (en) 2012-06-07
WO2012072791A3 (en) 2012-09-13
ES2418032B1 (es) 2014-10-06
ES2418032A2 (es) 2013-08-09

Similar Documents

Publication Publication Date Title
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
CU20110145A7 (es) Derivados de sulfonamida
ECSP12012334A (es) Morfolinopirimidinas y su uso en terapia
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
SV2010003767A (es) Compuestos pirazolicos 436
SV2010003777A (es) Compuestos organicos
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
JO3078B1 (ar) مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
IN2014CN04530A (es)
CA2912921C (en) Pyrazole compounds as modulators of fshr and uses thereof
MX2017008150A (es) Derivados de bencimidazol sulfonamidas como agonistas inversos del receptor gamma huerfano relacionado con el retinoide por gamma (t).
BR112012018955A2 (pt) combinação para administração simultânea, separada ou sequencial e ligante sigma ou um sal, isômero, pró-droga ou solvato farmaceuticamente aceitável do mesmo
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MX2013006420A (es) Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
PH12015502632A1 (en) Cxcr7 receptor modulators
GT201300322A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
ES2418032R1 (es) Derivados de 2-(1-fenil-4,5,6,7-tetrahidro-1h-indazol-4-il)etilamina utiles como inhibidores de receptores sigma
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2418032

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20141006

FA2A Application withdrawn

Effective date: 20150209